JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

Retrospective Analysis of Testicular Germ Cell Tumor Patients with Brain Metastases: A Single-Center Experience
Received Date : 05 Dec 2021
Accepted Date : 12 Mar 2022
Available Online : 31 Mar 2022
Doi: 10.37047/jos.2021-87403 - Article's Language: EN
J Oncol Sci. 2022;8(1):27-33
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Objective: We evaluated the survival characteristics of testicular germ cell tumor (GCT) patients with brain metastases (BM). Material and Methods: In this retrospective cross-sectional study, patients with relapsed or refractory GCT and BM were evaluated. The characteristic clinical features of the patients, their systemic treatments, local treatments applied to BM, and follow-up periods were recorded. The primary endpoint was to assess survival after detection of synchronous and metachronous BM. The secondary endpoint was determined as overall survival (OS). Results: Twenty-five patients were included in this study with median age and interquartile range (IQR) of 30.24 and 7.92, respectively. Stage IIIC was detected at first diagnosis in 72% of the patients. The most commonly used local BM treatment was the combination of surgery and radiotherapy (60%). The objective response rate (complete response plus partial response) after local BM treatment was 60%. The median OS in the whole group was 24.75 (IQR: 25.97) months. The median OS (IQR) in the synchronous BM group was significantly different than that in the metachronous BM group [33.51 (18.13) vs. 9.97 (7.52), 95% confidence interval of 6.7 to 40.3 months, p=0.013]. There was no difference in the median OS between the groups [median (IQR)=36.39 (25.35) months vs. 23.70 (35.68) months, p=0.672]. Conclusion: The patients with GCTs presenting with BM during diagnosis were in a better condition than those who developed BM at relapse. However, no significant difference was found in OS. This may indicate shorter survival times for the patients who relapse, as the tumor is resistant to systemic therapy.
KAYNAKLAR
  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. Erratum in: CA Cancer J Clin. 2021;71(4):359. [Crossref]  [PubMed] 
  2. Carver BS, Serio AM, Bajorin D, et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol. 2007;25(35):5603-5608. [Crossref]  [PubMed] 
  3. Yildiz B, Pinar Aral I, Balyemez U, et al. What is the optimal high-dose treatment following autologous stem cell transplantation in relapsed or refractory germ cell cancer: a retrospective comparison of high-dose ICE and high-dose CE. J BUON. 2020;25(2):1136-1140. [PubMed] 
  4. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594-603. [Crossref]  [PubMed] 
  5. International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Mollevi C, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28(33):4906-4911. [Crossref]  [PubMed] 
  6. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park). 1999;13(7):941-954, 957-961; discussion 961-962, 9. [PubMed] 
  7. Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24(4):878-888. [Crossref]  [PubMed]  [PMC] 
  8. Hardt A, Krell J, Wilson PD, et al. Brain metastases associated with germ cell tumors may be treated with chemotherapy alone. Cancer. 2014;120(11):1639-1646. [Crossref]  [PubMed] 
  9. Culine S, Kramar A, Théodore C, et al; Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol. 2008;26(3):421-427. [Crossref]  [PubMed] 
  10. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25(3):247-256. [Crossref]  [PubMed] 
  11. Barlow LJ, Badalato GM, McKiernan JM. Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol. 2010;7(11):610-7. [Crossref]  [PubMed] 
  12. Feldman DR, Lorch A, Kramar A, et al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options--an analysis from the Global Germ Cell Cancer Group. J Clin Oncol. 2016;34(4):345-351. [Crossref]  [PubMed]  [PMC] 
  13. Boyle HJ, Jouanneau E, Droz JP, Fléchon A. Management of brain metastases from germ cell tumors: a single center experience. Oncology. 2013;85(1):21-26. [Crossref]  [PubMed] 
  14. Wood MJ, Thomas R, Howard SA, Braschi-Amirfarzan M. Imaging of metastatic germ cell tumors in male patients from initial diagnosis to treatment-related toxicities: a primer for radiologists. AJR Am J Roentgenol. 2020;214(1):24-33. [Crossref]  [PubMed] 
  15. Pico JL, Rosti G, Kramar A, et al; Genito-Urinary Group of the French Federation of Cancer Centers (GETUG-FNCLCC), France; European Group for Blood and Marrow Transplantation (EBMT). A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16(7):1152-1159. [Crossref]  [PubMed] 
  16. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15(7):2559-2563. [Crossref]  [PubMed] 
  17. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A. 2002;99(7):4592-4595. [Crossref]  [PubMed]  [PMC] 
  18. Kalra M, Adra N, Hanna N, Abonour R, Einhorn LH. High-dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases. Cancer. 2020;126(6):1202-1207. [Crossref]  [PubMed] 
  19. Girones R, Aparicio J, Roure P, et al; Spanish Germ Cell Cancer Group (SGCCG). Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base. Clin Transl Oncol. 2014;16(11):959-965. [Crossref]  [PubMed] 
  20. Nonomura N, Nagahara A, Oka D, et al. Brain metastases from testicular germ cell tumors: a retrospective analysis. Int J Urol. 2009;16(11):887-893. [Crossref]  [PubMed]